Phase II trial of methyl-gag and melphalan in metastatic adult renal cell carcinoma

A trial of melphalan and methyl-gag was undertaken in 16 patients with metastatic renal cell carcinoma. Among 14 evaluable patients, 6 had stabilization of disease. No significant responses were observed. While both drugs have produced occasional responses in renal cancer, their combination shows no...

Full description

Saved in:
Bibliographic Details
Published inCancer investigation Vol. 8; no. 6; p. 623
Main Authors Guimaraes, J L, Ghosn, M, Ostronoff, M, Azab, M, Theodore, C, Droz, J P
Format Journal Article
LanguageEnglish
Published England 1990
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - secondary
Female
Humans
Kidney Neoplasms - drug therapy
Kidney Neoplasms - secondary
Male
Melphalan - administration & dosage
Middle Aged
Mitoguazone - administration & dosage
Online AccessGet more information

Cover

More Information
Summary:A trial of melphalan and methyl-gag was undertaken in 16 patients with metastatic renal cell carcinoma. Among 14 evaluable patients, 6 had stabilization of disease. No significant responses were observed. While both drugs have produced occasional responses in renal cancer, their combination shows no therapeutic advantage.
ISSN:0735-7907
DOI:10.3109/07357909009018930